Trials / Unknown
UnknownNCT03585530
Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus
Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Phase-II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Huai'an First People's Hospital · Academic / Other
- Sex
- All
- Age
- 70 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Concurrent chemoradiotherapy is one of the curative options for esophageal squamous cell carcinoma. We evaluated the efficacy and toxicity of raltitrexed with concurrent radiotherapy in elderly patients with esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | raltitrexed | Raltitrexed 2.6mg/m2 was administered on d1、d22 |
Timeline
- Start date
- 2018-09-05
- Primary completion
- 2022-01-30
- Completion
- 2022-03-15
- First posted
- 2018-07-13
- Last updated
- 2021-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03585530. Inclusion in this directory is not an endorsement.